<DOC>
	<DOCNO>NCT00691730</DOCNO>
	<brief_summary>This research study look kidney blood pressure change patient receive bevacizumab , aflibercept , sunitinib , cediranib cancer . Studying sample blood urine patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment antiangiogenic drug .</brief_summary>
	<brief_title>Kidney Blood Pressure Changes Patients Receiving Bevacizumab , Aflibercept , Sunitinib , Cediranib Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . To study renal blood pressure change patient treat bevacizumab , aflibercept , sunitinib malate , cediranib cancer . II . To determine physiological mechanism behind proteinuria hypertension induce antiangiogenic therapy ( i.e. , rarefaction ; imbalance eNOS , prostacyclin [ PGI_2 ] , prostaglandin E2 [ PGE_2 ] , thromboxane A2 [ TXA2 ] ; renin/aldosterone ; renovascular hypertension ) . III . To determine whether soluble factor ( like tyrosine kinase 1 [ sFlt1 ] , bFGF , VEGF ) steady state drug concentration predictive development proteinuria/hypertension . OUTLINE : This multicenter study . Patients undergo blood urine sample collection periodically . Urine sample assess PGI2 TXA2 level use validate ELISA method . Urine also assess protein creatinine level , microalbumin , osmolality , electrolytes . Blood sample assess pharmacokinetics sFlt1 , VEGF , bFGF level validate ELISA method . Blood sample also assess steady state drug concentration , renin , aldosterone level .</detailed_description>
	<criteria>Planning start treatment one follow antiangiogenic drug single agent combination chemotherapy cancer : Cediranib Bevacizumab Sunitinib malate Aflibercept Urinalysis negative protein OR 24hour urine protein &lt; 500 mg Prior chemotherapy within past 12 month allow More 12 month since prior antiangiogenic drug , include monoclonal antibody bind VEGF tyrosine kinase inhibitor block VEGFR2 At least 6 week since prior concurrent aldosterone receptor antagonist ( e.g. , spironolactone [ aldactone ] eplerenone ) No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>